CoChat

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker

Open access
Baselli, Guido Alessandro, Dongiovanni, Paola, Rametta, Raffaela, Meroni, Marica, Pelusi, Serena, Maggioni, Marco, Badiali, Sara, Pingitore, Piero, Maurotti, Samantha, Montalcini, Tiziana, Taliento, Alice Emma, Prati, Daniele, Rossi, Giorgio, Fracanzani, Anna Ludovica, Mancina, Rosellina Margherita, Romeo, Stefano, Valenti, Luca · 2020 · Gut
Cited by 106

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Objective: Efforts to manage non-alcoholic fatty liver disease (NAFLD) are limited by the incomplete understanding of the pathogenic mechanisms and the absence of accurate non-invasive biomarkers. The aim of this study was to identify novel NAFLD therapeutic targets andbiomarkers by conducting liver transcriptomic analysis in patients stratified by the presence of the PNPLA3 I148M genetic risk variant. Design: We sequenced the hepatic transcriptome of 125 obese individuals. ‘Severe NAFLD’ was defined as the presence of steatohepatitis, NAFLD activity score ≥4 or fibrosis stage ≥2. The circulating levels of the most upregulated transcript, interleukin-32 (IL32), were measured by ELISA. Results: Carriage of the PNPLA3 I148M variant correlated with the two major components of hepatic transcriptome variability and broadly influenced gene expression. In patients with severe NAFLD, there was an upregulation of inflammatory and lipid metabolism pathways. IL32 was the most robustly upregulated gene in the severe NAFLD group (adjusted p=1×10 −6 ), and its expression correlated with steatosis severity, both in I148M variant carriers and non-carriers. In 77 severely obese, and in a replication cohort of 160 individuals evaluated at the hepatology service, circulating IL32 levels were associated with both NAFLD and severe NAFLD independently of aminotransferases (p<0.01 for both). A linear combination of IL32-ALT-AST showed a better performance than ALT-AST alone in NAFLD diagnosis (area under the curve=0.92 vs 0.81, p=5×10 −5 ). Conclusion: Hepatic IL32 is overexpressed in NAFLD, correlates with hepatic fat and liver damage, and is detectable in the circulation, where it is independently associated with the presence and severity of NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2019-319226

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 106

Metadata

Authors
Baselli, G. A., Dongiovanni, P., Rametta, R., Meroni, M., Pelusi, S., Maggioni, M., Badiali, S., Pingitore, P., Maurotti, S., Montalcini, T., Taliento, A. E., Prati, D., Rossi, G., Fracanzani, A. L., Mancina, R. M., Romeo, S., & Valenti, L.
Venue
Gut
Publisher
BMJ
Published
2020-01-30
Volume
69
Issue
10
Pages
1855-1866
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3003313635
Cited by
106
References
13
FWCI
10.75
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. https://app.cochat.ai/papers/10.1136/gutjnl-2019-319226
The paper
Baselli, G. A., Dongiovanni, P., Rametta, R., Meroni, M., Pelusi, S., Maggioni, M., Badiali, S., Pingitore, P., Maurotti, S., Montalcini, T., Taliento, A. E., Prati, D., Rossi, G., Fracanzani, A. L., Mancina, R. M., Romeo, S., & Valenti, L. (2020). Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut. https://doi.org/10.1136/gutjnl-2019-319226

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.